Cognitive composites combine scores from multiple neuropsychological tests and demonstrate greater sensitivity to Alzheimer's disease (AD) related cognitive changes than individual tests. This review examines the development, composition and validity of cognitive composites to detect AD-related cognitive changes. The included cognitive composites were evaluated using four criteria: cognitive domains assessed; neuropsychological tests used, the inclusion of non-neuropsychological measures (e.g., Mini-Mental State Examination) that produce a global score themselves; and statistical methods used to calculate the composite. Existing composites fall into two categories: domain-specific (e.g., episodic memory, executive function, attention) or general composites combining multiple cognitive domains while incorporating clinical and functional measures. Psychometric properties were not consistently reported across all the studies. Therefore, a standardized validation framework is proposed to address these inconsistencies. Future work should focus on systematically evaluating optimized weighting, including data from clinical and functional measures and consistent psychometric reporting for assessing and monitoring cognitive dysfunction in early AD.
WeintraubSCarrilloMCFariasST, et al.Measuring cognition and function in the preclinical stage of Alzheimer's disease. Alzheimers Dement (N Y)2018; 4: 64–75.
2.
ColeyNGalliniAOussetP-J, et al.Evaluating the clinical relevance of a cognitive composite outcome measure: an analysis of 1414 participants from the 5-year GuidAge Alzheimer's prevention trial. Alzheimers Dement2016; 12: 1216–1225.
3.
Jack JrCRBennettDABlennowK, et al.NIA-AA Research framework: toward a biological definition of Alzheimer's disease. Alzheimers Dement2018; 14: 535–562.
4.
Serrano-PozoAFroschMPMasliahE, et al.Neuropathological alterations in Alzheimer disease. Cold Spring Harb Perspect Med2011; 1: a006189.
5.
Jack JrCRAndrewsJSBeachTG, et al.Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's association workgroup. Alzheimers Dement2024; 20: 5143–5169.
6.
BlackerDLeeHMuzikanskyA, et al.Neuropsychological measures in normal individuals that predict subsequent cognitive decline. Arch Neurol2007; 64: 862–871.
7.
DuboisBHampelHFeldmanHH, et al.Preclinical Alzheimer's disease: definition, natural history, and diagnostic criteria. Alzheimers Dement2016; 12: 292–323.
8.
SperlingRADonohueMCRamanR, et al.Trial of solanezumab in preclinical Alzheimer's disease. N Engl J Med2023; 389: 1096–1107.
9.
VillemagneVLDoreVBourgeatP, et al.Aβ-amyloid and tau imaging in dementia. Semin Nucl Med2017; 47: 75–88.
10.
MorminoECPappKV. Amyloid accumulation and cognitive decline in clinically normal older individuals: implications for aging and early Alzheimer's disease. J Alzheimers Dis2018; 64: S633–S646.
11.
RoweCCEllisKARimajovaM, et al.Amyloid imaging results from the Australian imaging, biomarkers and lifestyle (AIBL) study of aging. Neurobiol Aging2010; 31: 1275–1283.
12.
DonohueMCSperlingRAPetersenR, et al.Association between elevated brain amyloid and subsequent cognitive decline among cognitively normal persons. JAMA2017; 317: 2305–2316.
13.
RobertsROAakreJAKremersWK, et al.Prevalence and outcomes of amyloid positivity among persons without dementia in a longitudinal, population-based setting. JAMA Neurol2018; 75: 970–979.
14.
McDadeEBednarMMBrashearHR, et al.The pathway to secondary prevention of Alzheimer's disease. Alzheimers Dement2020; 6: e12069.
15.
CaselliRJLanglaisBTDueckAC, et al.Neuropsychological decline up to 20 years before incident mild cognitive impairment. Alzheimers Dement2020; 16: 512–523.
16.
BakerJELimYYPietrzakRH, et al.Cognitive impairment and decline in cognitively normal older adults with high amyloid-beta: a meta-analysis. Alzheimers Dement (Amst)2017; 6: 108–121.
17.
LimYYMaruffPPietrzakRH, et al.Abeta and cognitive change: examining the preclinical and prodromal stages of Alzheimer's disease. Alzheimers Dement2014; 10: 743–751 e741.
18.
MortamaisMAshJAHarrisonJ, et al.Detecting cognitive changes in preclinical Alzheimer's disease: a review of its feasibility. Alzheimers Dement2017; 13: 468–492.
19.
HarringtonKDDangCLimYY, et al.The effect of preclinical Alzheimer's disease on age-related changes in intelligence in cognitively normal older adults. Intelligence2018; 70: 22–29.
20.
AisenPSCummingsJJack JrCR, et al.On the path to 2025: understanding the Alzheimer's disease continuum. Alzheimers Res Ther2017; 9: 60.
21.
InselPSDonohueMCMackinRS, et al.Cognitive and functional changes associated with abeta pathology and the progression to mild cognitive impairment. Neurobiol Aging2016; 48: 172–181.
22.
JiSKangJHanC, et al.Potential role of APOE varepsilon4 allele as a modifier for the association of BDNF Val66Met polymorphisms and cognitive impairment in community-dwelling older adults. Front Aging Neurosci2024; 16: 1330193.
23.
BootsEASchultzSAClarkLR, et al.BDNF Val66met predicts cognitive decline in the Wisconsin registry for Alzheimer's prevention. Neurology2017; 88: 2098–2106.
24.
LimYYVillemagneVLLawsSM, et al.APOE And BDNF polymorphisms moderate amyloid beta-related cognitive decline in preclinical Alzheimer's disease. Mol Psychiatry2015; 20: 1322–1328.
25.
BellioMOxtobyNPWalkerZ, et al.Analyzing large Alzheimer's disease cognitive datasets: considerations and challenges. Alzheimers Dement (Amst)2020; 12: e12135.
26.
SongMKLinFCWardSE, et al.Composite variables: when and how. Nurs Res2013; 62: 45–49.
27.
JonaitisEMKoscikRLClarkLR, et al.Measuring longitudinal cognition: individual tests versus composites. Alzheimers Dement (Amst)2019; 11: 74–84.
28.
SchneiderLSGoldbergTE. Composite cognitive and functional measures for early stage Alzheimer's disease trials. Alzheimers Dement (Amst)2020; 12: e12017.
WatermeyerTCaliaC. Neuropsychological assessment in preclinical and prodromal Alzheimer disease: a global perspective. J Glob Health2019; 9: 010317.
31.
LimYYSnyderPJPietrzakRH, et al.Sensitivity of composite scores to amyloid burden in preclinical Alzheimer's disease: introducing the Z-scores of attention, verbal fluency, and episodic memory for nondemented older adults composite score. Alzheimers Dement (Amst)2016; 2: 19–26.
32.
BurnhamSCRaghavanNWilsonW, et al.Novel statistically-derived composite measures for assessing the efficacy of disease-modifying therapies in prodromal Alzheimer's disease trials: an AIBL study. J Alzheimers Dis2015; 46: 1079–1089.
33.
McKayNSMillarPRNicosiaJ, et al.Pick a PACC: comparing domain-specific-and general-cognitive composites in Alzheimer disease research. Neuropsychology2024; 38: 443–464.
34.
CranePKCarleAGibbonsLE, et al.Development and assessment of a composite score for memory in the Alzheimer's disease neuroimaging initiative (ADNI). Brain Imaging Behav2012; 6: 502–516.
35.
GibbonsLECarleACMackinRS, et al.A composite score for executive functioning, validated in Alzheimer's disease neuroimaging initiative (ADNI) participants with baseline mild cognitive impairment. Brain Imaging Behav2012; 6: 517–527.
36.
ChoiSEMukherjeeSGibbonsLE, et al.Development and validation of language and visuospatial composite scores in ADNI. Alzheimers Dement2020; 6: e12072.
37.
CutterGRBaierMLRudickRA, et al.Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain1999; 122: 871–882.
AmaefuleCODyrbaMWolfsgruberS, et al.Association between composite scores of domain-specific cognitive functions and regional patterns of atrophy and functional connectivity in the Alzheimer’s disease spectrum. Neuroimage Clin2021; 29: 102533.
40.
CalamiaMMarkonKTranelD. The robust reliability of neuropsychological measures: meta-analyses of test–retest correlations. Clin Neuropsychol2013; 27: 1077–1105.
41.
LangbaumJBEllisonNNCaputoA, et al.The Alzheimer's prevention initiative composite cognitive test: a practical measure for tracking cognitive decline in preclinical Alzheimer's disease. Alzheimers Res Ther2020; 12: 66.
42.
FolsteinMFFolsteinSEMcHughPR. Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res1975; 12: 189–198.
43.
MioshiEDawsonKMitchellJ, et al.The addenbrooke's cognitive examination revised (ACE-R): a brief cognitive test battery for dementia screening. Int J Geriatr Psychiatry2006; 21: 1078–1085.
44.
NasreddineZSPhillipsNABedirianV, et al.The Montreal cognitive assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc2005; 53: 695–699.
45.
KueperJKSpeechleyMMontero-OdassoM. The Alzheimer's disease assessment scale-cognitive subscale (ADAS-cog): modifications and responsiveness in pre-dementia populations. A narrative review. J Alzheimers Dis2018; 63: 423–444.
46.
MorrisJC. The clinical dementia rating (CDR): current version and scoring rules. Neurology1993; 43: 2412–2414.
47.
JuttenRJPappKVHendrixS, et al.Why a clinical trial is as good as its outcome measure: a framework for the selection and use of cognitive outcome measures for clinical trials of Alzheimer's disease. Alzheimers Dement2023; 19: 708–720.
48.
BorlandEEdgarCStomrudE, et al.Clinically relevant changes for cognitive outcomes in preclinical and prodromal cognitive stages. Neurology2022; 99: e1142–e1153.
49.
AndradeC. Multiple testing and protection against a type 1 (false positive) error using the Bonferroni and hochberg corrections. Indian J Psychol Med2019; 41: 99–100.
50.
AyutyanontNLangbaumJBHendrixSB, et al.The Alzheimer's prevention initiative composite cognitive test score: sample size estimates for the evaluation of preclinical Alzheimer's disease treatments in presenilin 1 E280A mutation carriers. J Clin Psychiatry2014; 75: 652–660.
51.
HamptonOLMukherjeeSProperziMJ, et al.Harmonizing the preclinical Alzheimer cognitive composite for multicohort studies. Neuropsychology2023; 37: 436–449.
52.
KimMYiDByunMS, et al.Development of a cognitive composite for preclinical Alzheimer's disease in Korean older adults. J Alzheimers Dis2023; 96: 633–641.
53.
KittnerSJWhiteLRFarmerME, et al.Methodological issues in screening for dementia: the problem of education adjustment. J Chronic Dis1986; 39: 163–170.
MaruffPLimYYDarbyD, et al.Clinical utility of the cogstate brief battery in identifying cognitive impairment in mild cognitive impairment and Alzheimer's disease. BMC Psychol2013; 1: 30.
56.
StaffaroniAMAskenBMCasalettoKB, et al.Development and validation of the uniform data set (v3.0) executive function composite score (UDS3-EF). Alzheimers Dement2021; 17: 574–583.
57.
AschenbrennerAJBalotaDAFaganAM, et al.Alzheimer disease cerebrospinal fluid biomarkers moderate baseline differences and predict longitudinal change in attentional control and episodic memory composites in the adult children study. J Int Neuropsychol Soc2015; 21: 573–583.
58.
BrookerHWilliamsGHampshireA, et al.FLAME: a computerized neuropsychological composite for trials in early dementia. Alzheimers Dement (Amst)2020; 12: e12098.
59.
HarringtonKDLimYYEllisKA, et al.The association of aβ amyloid and composite cognitive measures in healthy older adults and MCI. Int Psychogeriatr2013; 25: 1667–1677.
60.
PappKVRentzDMOrlovskyI, et al.Optimizing the preclinical Alzheimer's cognitive composite with semantic processing: the PACC5. Alzheimers Dement2017; 3: 668–677.
61.
HahnAKimYJKimHJ, et al.The preclinical amyloid sensitive composite to determine subtle cognitive differences in preclinical Alzheimer's disease. Sci Rep2020; 10: 13583.
62.
StrickerNHTwohyELAlbertsonSM, et al.Mayo-PACC: a parsimonious preclinical Alzheimer's disease cognitive composite comprised of public-domain measures to facilitate clinical translation. Alzheimers Dement2023; 19: 2575–2584.
63.
WangQChenGSchindlerSE, et al.Baseline microglial activation correlates with brain amyloidosis and longitudinal cognitive decline in Alzheimer disease. Neurol Neuroimmunol Neuroinflamm2022; 9: e1152.
64.
WesselsAMSiemersERYuP, et al.A combined measure of cognition and function for clinical trials: the integrated Alzheimer's disease rating scale (iADRS). J Prev Alzheimers Dis2015; 2: 227–241.
65.
WangJLogovinskyVHendrixSB, et al.ADCOMS: a composite clinical outcome for prodromal Alzheimer's disease trials. J Neurol Neurosurg Psychiatry2016; 87: 993–999.
66.
JuttenRJHarrisonJEBrunnerAJ, et al.The cognitive-functional composite is sensitive to clinical progression in early dementia: longitudinal findings from the catch-cog study cohort. Alzheimers Dement2020; 6: e12020.
67.
HuangYItoKBilling JrCB, et al.Development of a straightforward and sensitive scale for MCI and early AD clinical trials. Alzheimers Dement2015; 11: 404–414.
68.
JuttenRJHarrisonJELee Meeuw KjoePR, et al.Assessing cognition and daily function in early dementia using the cognitive-functional composite: findings from the catch-cog study cohort. Alzheimers Res Ther2019; 11: 45.
69.
SnyderPJKahle-WrobleskiKBrannanS, et al.Assessing cognition and function in Alzheimer's disease clinical trials: do we have the right tools?Alzheimers Dement2014; 10: 853–860.
70.
KozauerNKatzR. Regulatory innovation and drug development for early-stage Alzheimer's disease. N Engl J Med2013; 368: 1169–1171.
71.
RodriguesIBAdachiJDBeattieKA, et al.Determining known-group validity and test-retest reliability in the PEQ (personalized exercise questionnaire). BMC Musculoskelet Disord2019; 20: 373.
72.
GonzálezDAKarstensAJPatelSES, et al.The Parkinson's disease cognitive composite: lessons forgotten from preclinical Alzheimer's cognitive composites. Mov Disord2025; 40: 1442–1443.
73.
ClarkLAWatsonD. Constructing validity: new developments in creating objective measuring instruments. Psychol Assess2019; 31: 1412–1427.
74.
FlakeJKPekJHehmanE. Construct validation in social and personality research: current practice and recommendations. Soc Psychol Personal Sci2017; 8: 370–378.
75.
DonohueMCSunC-KRamanR, et al.Cross-validation of optimized composites for preclinical Alzheimer's disease. Alzheimers Dement (N Y)2017; 3: 123–129.
76.
LangbaumJBHendrixSBAyutyanontN, et al.An empirically derived composite cognitive test score with improved power to track and evaluate treatments for preclinical Alzheimer's disease. Alzheimers Dement2014; 10: 666–674.
77.
PosnerHCurielREdgarC, et al.Outcomes assessment in clinical trials of Alzheimer's disease and its precursors: readying for short-term and long-term clinical trial needs. Innov Clin Neurosci2017; 14: 22–29.
78.
McDougallFEdgarCMertesM, et al.Psychometric properties of the clinical dementia rating - sum of boxes and other cognitive and functional outcomes in a prodromal Alzheimer's disease population. J Prev Alzheimers Dis2021; 8: 151–160.
79.
MokkinkLBPrinsenCABouterLM, et al.The COnsensus-based standards for the selection of health measurement INstruments (COSMIN) and how to select an outcome measurement instrument. Braz J Phys Ther2016; 20: 105–113.
